REMARKS

Claims 28 to 47 as amended are present.

The Examiner indicates that

"Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 27-45, drawn to a composition, classified in class 424, subclass 465.

II. Claims 46, 47, drawn to a method of using, classified in class 514, subclass 824."

Applicants' elect Group II Claims 46 and 47.

Claims 28 to 45 have been amended to make them method claims which depend from Claim 46. Claims 28 to 45, 47 are readable on elected Claim 46.

It is believed that this application is in good form for examination.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4336

Date: November 7, 2002

Burton Rodney
Attorney for Applicants
Reg. No. 22,076

VERSION WITH MARKINGS TO SHOW CHANGES

In the Claims:

Please cancel Claim 27.

Please amend Claims 28 to 45 as follows.

-- 28. (Amended) The [pharmaceutical composition] method as defined in Claim [27] 46 [wherein] where in the pharmaceutical composition administered the statin and aspirin are formulated together in the same dosage formulation. --

-- 29. (Amended) The [pharmaceutical composition] method as defined in Claim 28 [wherein] where in the pharmaceutical composition administered the statin and aspirin are formulated together in a single tablet. --

-- 30. (Amended) The [pharmaceutical composition] method as defined in Claim 29 wherein the tablet administered includes a core and a coating layer surrounding said core and wherein one of the statin and aspirin is present in the core and the other is present in the coating layer surrounding the core. --

-- 31. (Amended) The [pharmaceutical composition] method as defined in Claim 30 wherein the aspirin is present in the core and the statin is present in the coating layer. --

-- 32. (Amended) The [pharmaceutical composition] method as defined in Claim 31 wherein the coating layer also includes one or more buffering agents. --

-- 33. (Amended) The [pharmaceutical composition] method as defined in Claim [27] 46 wherein the statin is pravastatin[, lovastatin, simvastatin, fluvastatin, atorvastatin or cerivastatin]. --

-- 34. (Amended) The [pharmaceutical composition] method as defined in Claim [27] 46 wherein the pharmaceutical composition administered further [including] includes one or more buffering agents in combination with the statin. --

-- 35. (Amended) The [pharmaceutical composition] method as defined in Claim 29 wherein the tablet administered further [including] includes an outer protective coating or finishing layer surrounding said tablet. --

-- 36. (Amended) The [pharmaceutical composition] method as defined in Claim [27] 46 wherein the aspirin in the pharmaceutical composition administered is in the form of enteric coated aspirin granules. --

-- 37. (Amended) The [pharmaceutical composition] method as defined in Claim 36 wherein the pharmaceutical composition administered is in the form of tablets or granules contained in a capsule. --

-- 38. (Amended) The [pharmaceutical composition] method as defined in Claim 36 wherein the enteric coated aspirin granules include a finishing overcoat, and the coated aspirin and the statin are in the form of a tablet or capsule. --

-- 39. (Amended) The [pharmaceutical composition] method as defined in Claim 38 wherein the coated aspirin granules and the statin in the form of granules are contained in the same capsule shells. --

-- 40. (Amended) The [pharmaceutical composition] method as defined in Claim 28 [wherein] where in the pharmaceutical composition administered the aspirin is in the form of enteric coated granules of aspirin and the statin is in the form of enteric coated granules of statin, in the form of compressed tablets or capsules. --

-- 41. (Amended) The [pharmaceutical composition] method as defined in Claim [27] 46 wherein the pharmaceutical composition administered is in the form of a tablet or capsule containing both aspirin granules and statin granules. --

-- 42. (Amended) The [pharmaceutical composition] method as defined in Claim 41 wherein the statin is in the form of enteric coated statin granules. --

-- 43. (Amended) The [pharmaceutical composition] method as defined in Claim 41 wherein the statin granules include an outer protective coating to protect against interaction with aspirin. --

-- 44. (Amended) The [pharmaceutical composition] method as defined in Claim [27] ] 46 wherein the pharmaceutical composition administered further [including] includes an antioxidant. --

-- 45. (Amended) The [pharmaceutical composition] method as defined in Claim 44 wherein the antioxidant is vitamin C and/or vitamin E. --